909 related articles for article (PubMed ID: 17554481)
21. Long-term treatment of refractory posterior uveitis with anti-TNFalpha (infliximab).
Benitez-del-Castillo JM; Martinez-de-la-Casa JM; Pato-Cour E; Méndez-Fernández R; López-Abad C; Matilla M; Garcia-Sanchez J
Eye (Lond); 2005 Aug; 19(8):841-5. PubMed ID: 15389273
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of anti-TNF alpha in severe and/or refractory Behçet's disease: Multicenter study of 124 patients.
Vallet H; Riviere S; Sanna A; Deroux A; Moulis G; Addimanda O; Salvarani C; Lambert M; Bielefeld P; Seve P; Sibilia J; Pasquali J; Fraison J; Marie I; Perard L; Bouillet L; Cohen F; Sene D; Schoindre Y; Lidove O; Le Hoang P; Hachulla E; Fain O; Mariette X; Papo T; Wechsler B; Bodaghi B; Rigon MR; Cacoub P; Saadoun D;
J Autoimmun; 2015 Aug; 62():67-74. PubMed ID: 26162757
[TBL] [Abstract][Full Text] [Related]
23. A single infliximab infusion vs corticosteroids for acute panuveitis attacks in Behçet's disease: a comparative 4-week study.
Markomichelakis N; Delicha E; Masselos S; Fragiadaki K; Kaklamanis P; Sfikakis PP
Rheumatology (Oxford); 2011 Mar; 50(3):593-7. PubMed ID: 21097877
[TBL] [Abstract][Full Text] [Related]
24. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet's disease with refractory uveoretinitis.
Ohno S; Nakamura S; Hori S; Shimakawa M; Kawashima H; Mochizuki M; Sugita S; Ueno S; Yoshizaki K; Inaba G
J Rheumatol; 2004 Jul; 31(7):1362-8. PubMed ID: 15229958
[TBL] [Abstract][Full Text] [Related]
25. Long-term infliximab treatment for Behçet's disease.
Takamoto M; Kaburaki T; Numaga J; Fujino Y; Kawashima H
Jpn J Ophthalmol; 2007; 51(3):239-40. PubMed ID: 17554493
[No Abstract] [Full Text] [Related]
26. Intravitreal infliximab for sight-threatening relapsing uveitis in Behçet disease: a pilot study in 15 patients.
Markomichelakis N; Delicha E; Masselos S; Sfikakis PP
Am J Ophthalmol; 2012 Sep; 154(3):534-541.e1. PubMed ID: 22789563
[TBL] [Abstract][Full Text] [Related]
27. The effect of anti-tumour necrosis factor alpha (infliximab) on sight-threatening uveitis in a patient with Behçet's disease.
Morris DS; Gavin MP; Sturrock RD
Adv Exp Med Biol; 2003; 528():557-9. PubMed ID: 12918763
[No Abstract] [Full Text] [Related]
28. Combined cyclosporine and corticosteroid therapy for sight-threatening uveitis in Behçet's disease.
Whitcup SM; Salvo EC; Nussenblatt RB
Am J Ophthalmol; 1994 Jul; 118(1):39-45. PubMed ID: 8023874
[TBL] [Abstract][Full Text] [Related]
29. Induction of regulatory T cells by infliximab in Behcet's disease.
Sugita S; Yamada Y; Kaneko S; Horie S; Mochizuki M
Invest Ophthalmol Vis Sci; 2011 Jan; 52(1):476-84. PubMed ID: 20861484
[TBL] [Abstract][Full Text] [Related]
30. INTRAVITREAL INFLIXIMAB IN REFRACTORY UVEITIS IN BEHCET'S DISEASE: A Safety and Efficacy Clinical Study.
Hamza MM; Macky TA; Sidky MK; Ragab G; Soliman MM
Retina; 2016 Dec; 36(12):2399-2408. PubMed ID: 27870802
[TBL] [Abstract][Full Text] [Related]
31. Induction of ocular Behçet's disease remission after short-term treatment with infliximab: a case series of 11 patients with a follow-up from 4 to 16 years.
Sfikakis PP; Arida A; Ladas DS; Markomichelakis N
Clin Exp Rheumatol; 2019; 37 Suppl 121(6):137-141. PubMed ID: 31856941
[TBL] [Abstract][Full Text] [Related]
32. [Clinical observation of 85 patients with Behçet's uveitis treated with immunosuppressive agents combined with steroids].
Zhao M; Wang H; Jiao X; Wei WB
Zhonghua Yan Ke Za Zhi; 2013 Mar; 49(3):202-6. PubMed ID: 23866699
[TBL] [Abstract][Full Text] [Related]
33. Treatment of intestinal Behçet's syndrome with chimeric tumour necrosis factor alpha antibody.
Travis SP; Czajkowski M; McGovern DP; Watson RG; Bell AL
Gut; 2001 Nov; 49(5):725-8. PubMed ID: 11600479
[TBL] [Abstract][Full Text] [Related]
34. Clinical experience with adalimumab in the treatment of ocular Behçet disease.
Bawazeer A; Raffa LH; Nizamuddin SH
Ocul Immunol Inflamm; 2010 Jun; 18(3):226-32. PubMed ID: 20482404
[TBL] [Abstract][Full Text] [Related]
35. Improvement of neurological and ocular symptoms of Behçet's disease after the introduction of infliximab.
Barešić M; Reihl M; Habek M; Vukojević N; Anić B
Rheumatol Int; 2018 Jul; 38(7):1301-1306. PubMed ID: 29777341
[TBL] [Abstract][Full Text] [Related]
36. Cataract surgery under infliximab therapy in a patient with Behçet's disease.
Noda E; Yamanishi S; Shiraishi A; Ohashi Y
J Ocul Pharmacol Ther; 2009 Oct; 25(5):467-70. PubMed ID: 19857109
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of combination therapy of anti-TNF-α antibody infliximab and methotrexate in refractory entero-Behçet's disease.
Iwata S; Saito K; Yamaoka K; Tsujimura S; Nawata M; Hanami K; Tanaka Y
Mod Rheumatol; 2011 Apr; 21(2):184-91. PubMed ID: 21052764
[TBL] [Abstract][Full Text] [Related]
38. Interferon alpha for ocular Behçet's disease.
Pivetti-Pezzi P; Accorinti M; Pirraglia MP; Priori R; Valesini G
Acta Ophthalmol Scand; 1997 Dec; 75(6):720-2. PubMed ID: 9527339
[TBL] [Abstract][Full Text] [Related]
39. Infliximab in the treatment of refractory posterior uveitis.
Joseph A; Raj D; Dua HS; Powell PT; Lanyon PC; Powell RJ
Ophthalmology; 2003 Jul; 110(7):1449-53. PubMed ID: 12867408
[TBL] [Abstract][Full Text] [Related]
40. Long-term efficacy of infliximab on background vascular leakage in patients with Behçet's disease.
Keino H; Okada AA; Watanabe T; Taki W
Eye (Lond); 2014 Sep; 28(9):1100-6. PubMed ID: 24946845
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]